MDM1EA

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Infobox drug

| drug_name =

| image = MDM1EA.svg

| width =

| caption =

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_CA =

| licence_EU =

| DailyMedID =

| licence_US =

| pregnancy_AU =

| pregnancy_category =

| dependency_liability =

| addiction_liability =

| routes_of_administration =

| class =

| ATC_prefix =

| ATC_suffix =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number = 121734-65-4

| CAS_supplemental =

| PubChem = 6424509

| PubChemSubstance =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID = 4930000

| UNII =

| KEGG =

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = N-Methyl-1-(3,4-methylenedioxyphenyl)-1-ethanamine; MDM1EA; α,N-Dimethyl-3,4-methylenedioxybenzylamine; α,N-DMMDBA; α,N-Dimethylpiperonylamine; α,N-Dimethyl-1,3-benzodioxole-5-methanamine

| IUPAC_name = 1-(1,3-benzodioxol-5-yl)-N-methylethanamine

| C=10 | H=13 | N=1 | O=2

| SMILES = CC(C1=CC2=C(C=C1)OCO2)NC

| StdInChI = 1S/C10H13NO2/c1-7(11-2)8-3-4-9-10(5-8)13-6-12-9/h3-5,7,11H,6H2,1-2H3

| StdInChIKey = USAUUVXZKYYZIL-UHFFFAOYSA-N

}}

N-Methyl-1-(3,4-methylenedioxyphenyl)-1-ethanamine (MDM1EA), also known as α,N-dimethyl-3,4-methylenedioxybenzylamine (α,N-DMMDBA) or as α,N-dimethylpiperonylamine, is an entactogen-like drug of the benzylamine family related to MDMA.{{cite book | vauthors = Shulgin A, Manning T, Daley PF | chapter = #45. α,N-DMMDBA | pages = 80–81 | chapter-url = https://archive.org/details/shulgin-index-vol-1/page/80/mode/1up | title = The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds | publisher = Transform Press | location = Berkeley, CA | volume = 1 | year = 2011 | isbn = 978-0-9630096-3-0 | oclc = 709667010 }}{{cite book | vauthors = Trachsel D, Lehmann D, Enzensperger C | title=Phenethylamine: von der Struktur zur Funktion | trans-title = Phenethylamines: From Structure to Function | publisher=Nachtschatten-Verlag | location=Solothurn | series=Nachtschatten-Science | year=2013 | isbn=978-3-03788-700-4 | oclc=858805226 | url=https://books.google.com/books?id=-Us1kgEACAAJ | language=de | access-date=29 January 2025 | page=594 }}{{cite journal | vauthors = Bronson ME, Barrios-Zambrano L, Jiang W, Clark CR, DeRuiter J, Newland MC | title = Behavioral and developmental effects of two 3,4-methylenedioxymethamphetamine (MDMA) derivatives | journal = Drug and Alcohol Dependence | volume = 36 | issue = 3 | pages = 161–166 | date = December 1994 | pmid = 7889806 | doi = 10.1016/0376-8716(94)90141-4 }} It is the analogue of MDMA in which the side chain has been shortened by one carbon atom.

The drug has been found to be a weak serotonin reuptake inhibitor and partially substituted for MDMA in rodent drug discrimination tests at the highest assessed doses.{{cite journal | vauthors = Hashimoto K, Maeda H, Goromaru T | title = Antagonism of 3,4-methylenedioxymethamphetamine-induced neurotoxicity in rat brain by 1-piperonylpiperazine | journal = European Journal of Pharmacology | volume = 228 | issue = 2–3 | pages = 171–174 | date = September 1992 | pmid = 1280228 | doi = 10.1016/0926-6917(92)90027-a }} The effects of α,N-DMMDBA in humans are unknown.

It is not a controlled substance in the United States as of 2011.

Homo-MDMA (HMDMA), an analogue of MDMA in which the side chain was extended by one carbon atom, has also been synthesized and studied. It partially substituted for MDMA similarly to MDM1EA.